Dramatic Response to Stopping Antiandrogen Treatment in Prostate Cancer
Author Information
Author(s): Lau Yiu-Keung, Chadha Manpreet K, Litwin Alan, Trump Donald L
Primary Institution: West Virginia University; Roswell Park Cancer Institute
Hypothesis
Can discontinuing the antiandrogen agent bicalutamide lead to significant improvements in prostate cancer patients?
Conclusion
The case demonstrates a significant and sustained decline in PSA levels and radiologic improvement after stopping bicalutamide in a patient with metastatic prostate cancer.
Supporting Evidence
- The patient's PSA levels dropped significantly after stopping bicalutamide.
- Imaging showed a remarkable reduction in cancerous adenopathy after treatment cessation.
- The patient maintained a good clinical status for an extended period following the withdrawal.
Takeaway
When a patient with prostate cancer stopped taking a certain medication, their cancer markers improved a lot, showing that sometimes stopping a treatment can help.
Methodology
The case study involved monitoring PSA levels and imaging studies before and after the discontinuation of bicalutamide.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
The patient was a 75-year-old African American man.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website